FDA 483 - 3D Imaging Drug Design and Development - January 31, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of 3D Imaging Drug Design and Development, a PET Drug Producer in Little Rock, AR, revealed significant deficiencies in their written procedures. The firm lacked adequate procedures for the receipt, evaluation, and reporting of post-marketing adverse drug experiences, as well as for the correct retention timeframe of drug product complaint records. These issues indicate a failure to establish proper controls for drug safety reporting and complaint handling.
ID · b21c2326-aca9-4c9b-861d-baa1a8c486b6